.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A05A_BileTherapy.A05AA02_UrsodeoxycholicAcid.UrsodeoxycholicAcid .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A05A_BileTherapy.A05AA02_UrsodeoxycholicAcid.UrsodeoxycholicAcid| name: | UrsodeoxycholicAcid |
| ATC code: | A05AA02 | route: | oral |
| n-compartments | 1 |
Ursodeoxycholic acid (UDCA) is a secondary bile acid used for the treatment of primary biliary cholangitis (PBC) and certain cholestatic liver diseases. It works by reducing the absorption of cholesterol and protecting liver cells. It is an approved drug and remains the standard therapy for PBC and certain pediatric cholestatic conditions.
Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, after single oral administration.
Yoon, S, et al., & Chung, JY (2021). Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clinical pharmacology in drug development 10(1) 68–77. DOI:10.1002/cpdd.790 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32191400
Zuo, P, et al., & Young, MA (2016). A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis. CPT: pharmacometrics & systems pharmacology 5(8) 418–426. DOI:10.1002/psp4.12100 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27537780
Gordi, T, et al., & Blood, AB (2014). Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry. Journal of clinical pharmacology 54(9) 1031–1037. DOI:10.1002/jcph.327 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24805288